Charting a course to therapeutics for difficult-to-treat cancer
Who We Are


Pipeline
Our Science
Antibody-drug conjugates (ADCs)


Immuno-oncology (I/O)
Despite the introduction of I/O approaches that activate one’s own immune system to fight cancer, many patients are unfortunately still unable to overcome complex, difficult-to-treat disease. Pyxis is advancing a diverse portfolio of immunotherapies that target broad immune regulatory mechanisms as well as novel immune checkpoints with the potential to transform the cancer treatment landscape.
HOT TUMOR DISCOVERY PLATFORM
“Hot” tumors typically contain numbers of tumor-infiltrating immune cells (TILs). The tumor micro-environment is often inhibitory of their activity.
Using advances in comparative gene profiling between functional and inhibited or dysfunctional TILs, we are designing therapies to enhance the anti-tumor immune response in the tumor microenvironment.
Cold tumor discovery platform


Our Team
Lara S. Sullivan, M.D.
Chief Executive Officer
Robert Crane
Chief Financial Officer
Ronald Herbst, Ph.D.
Chief Scientific Officer
Steve Monks
Chief Technical Officer
Ritu Shah, PMP
Chief Operating Officer
James Mutamba, Ph.D.
Vice President of Business and Corporate Development
Board Members
Lara S. Sullivan, M.D.
Chief Executive Officer
David Steinberg
Founding CEO and Chairman
John Flavin
Co-founder, Founding Chairman and Independent Director
Christian Schetter, Ph.D.
Director
Gotham Makker, M.D.
Director
Lucio Iannone, Ph.D.
Director
Christopher O’Donnell, Ph.D.
Director
Scientific Advisory Board
Thomas Gajewski, M.D., Ph.D.
University of Chicago
Michael B. Atkins, M.D.
Georgetown-Lombardi Comprehensive Cancer Center
Lisa H. Butterfield, Ph.D.
Parker Institute for Cancer Immunotherapy
University of California San Francisco
Alan Korman, Ph.D.
Vir Biotechnology, Inc.
Jason J. Luke, M.D., FACP
UPMC Hillman Cancer Center and University of Pittsburgh
Investors







































